ATE503469T1 - Nanoteilchen zur abgabe von nukleinsäure - Google Patents
Nanoteilchen zur abgabe von nukleinsäureInfo
- Publication number
- ATE503469T1 ATE503469T1 AT07764504T AT07764504T ATE503469T1 AT E503469 T1 ATE503469 T1 AT E503469T1 AT 07764504 T AT07764504 T AT 07764504T AT 07764504 T AT07764504 T AT 07764504T AT E503469 T1 ATE503469 T1 AT E503469T1
- Authority
- AT
- Austria
- Prior art keywords
- nanoparticles
- release
- nucleic acid
- chitosan
- rna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Nanotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81920906P | 2006-07-07 | 2006-07-07 | |
PCT/DK2007/050084 WO2008003329A2 (en) | 2006-07-07 | 2007-07-06 | Nanoparticles for nucleic acid delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE503469T1 true ATE503469T1 (de) | 2011-04-15 |
Family
ID=38754461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07764504T ATE503469T1 (de) | 2006-07-07 | 2007-07-06 | Nanoteilchen zur abgabe von nukleinsäure |
Country Status (8)
Country | Link |
---|---|
US (1) | US20100015232A1 (de) |
EP (3) | EP2397123A1 (de) |
AT (1) | ATE503469T1 (de) |
CA (1) | CA2706124A1 (de) |
DE (1) | DE602007013559D1 (de) |
DK (1) | DK2037899T3 (de) |
ES (1) | ES2362376T3 (de) |
WO (1) | WO2008003329A2 (de) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2662560A1 (en) | 2006-09-15 | 2008-03-20 | Fmc Biopolymer As | Oligonucleotide non-viral delivery systems |
WO2009048958A2 (en) * | 2007-10-08 | 2009-04-16 | The Board Of Regents Of The University Of Texas System | Methods and compositions involving chitosan nanoparticles |
WO2011046983A2 (en) | 2009-10-12 | 2011-04-21 | Smith Holdings, Llc | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
FR2963351B1 (fr) | 2010-07-30 | 2013-03-08 | Univ Claude Bernard Lyon | Particules formees d'un complexe polyelectrolyte de chitosane et d'un polysaccharide anionique, presentant une stabilite amelioree |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
PL3590949T3 (pl) | 2010-10-01 | 2022-08-29 | Modernatx, Inc. | Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania |
WO2012094574A2 (en) * | 2011-01-06 | 2012-07-12 | The Johns Hopkins University | Stabilized polyribonucleotide nanoparticles |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US20140017330A1 (en) * | 2011-04-04 | 2014-01-16 | Board Of Regents Of The University Of Nebraska | Activated Nucleoside Analog Conjugates and Methods of Use Thereof |
US20150087689A1 (en) | 2011-05-24 | 2015-03-26 | Polyvalor, Limited Partnership | COMPOSITIONS AND METHODS FOR EFFICACIOUS AND SAFE DELIVERY OF siRNA USING SPECIFIC CHITOSAN-BASED NANOCOMPLEXES |
US8841272B2 (en) * | 2011-05-31 | 2014-09-23 | Kansas State University Research Foundation | Double-stranded RNA-based nanoparticles for insect gene silencing |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
AU2012318752B2 (en) | 2011-10-03 | 2017-08-31 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
LT2791160T (lt) | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modifikuotos mrnr sudėtys |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
BR112015004902A2 (pt) | 2012-09-05 | 2017-07-04 | Chase Pharmaceuticals Corp | métodos e composição neutroprotetores anticolinérgicos |
US9801953B2 (en) | 2012-10-15 | 2017-10-31 | Emory University | Nanoparticles carrying nucleic acid cassettes for expressing RNA |
JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
WO2014152030A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Removal of dna fragments in mrna production process |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP2971033B8 (de) | 2013-03-15 | 2019-07-10 | ModernaTX, Inc. | Herstellungsverfahren zur herstellung von rna-transkripten |
US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
EP2971161B1 (de) | 2013-03-15 | 2018-12-26 | ModernaTX, Inc. | Nukleinsäurereinigung |
DK3019619T3 (da) | 2013-07-11 | 2021-10-11 | Modernatx Inc | Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
WO2015051169A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
LT3134131T (lt) | 2014-04-23 | 2022-02-10 | Modernatx, Inc. | Nukleorūgšties vakcinos |
AU2015271295B2 (en) * | 2014-06-06 | 2020-04-16 | Merck Patent Gmbh | Antigen-loaded chitosan nanoparticles for immunotherapy |
JP2017522028A (ja) | 2014-07-16 | 2017-08-10 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 環状ポリヌクレオチド |
US9724307B2 (en) | 2015-02-24 | 2017-08-08 | San Heh Pharmaceutical Corporation | Crosslinked nanoparticle composition |
US11434486B2 (en) | 2015-09-17 | 2022-09-06 | Modernatx, Inc. | Polynucleotides containing a morpholino linker |
MX2018013122A (es) * | 2016-04-26 | 2019-03-28 | Viaqua Therapeutics Ltd | Composiciones y procedimientos para tratar infecciones viricas en gambas. |
EP3552632B1 (de) * | 2016-12-07 | 2023-07-12 | Stelic Institute & Co., Inc. | Medizinische zusammensetzung zur behandlung und prävention von chronisch-entzündlichen darmerkrankungen |
US20210315214A1 (en) | 2018-07-03 | 2021-10-14 | Inl - International Iberian Nanotechnology Laboratory | Pesticide |
CN110396524B (zh) * | 2019-05-31 | 2023-05-02 | 海南大学 | 一种用于蚊虫的RNAi纳米颗粒和制备方法及用途 |
KR102604882B1 (ko) * | 2021-07-01 | 2023-11-21 | 인천대학교 산학협력단 | 신규 특이적 항암 및 항염증 siRNA 및 이의 용도 |
WO2023084510A1 (en) | 2021-11-09 | 2023-05-19 | Viaqua Therapeutics Ltd. | Compositions for aquaculturing |
IT202100032393A1 (it) | 2021-12-23 | 2023-06-23 | Torino Politecnico | Metodo per la preparazione di nanoparticelle polimeriche ibride per il rilascio di farmaci oligonucleotidici nelle terapie farmacologiche a scopo rigenerativo, curativo e preventivo |
CN115992131A (zh) * | 2022-07-22 | 2023-04-21 | 江苏省农业科学院 | 一种纳米化壳聚糖/dsGRK复合体及其制备方法和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030134810A1 (en) * | 2001-10-09 | 2003-07-17 | Chris Springate | Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents |
US20040063654A1 (en) * | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
NO317653B1 (no) * | 2002-05-03 | 2004-11-29 | Stiftelsen Biopolymer | Formulering som omfatter komplekser av kitosanoligomerer og nukleinsyre, fremgangsmate for a fremstille formuleringen samt anvendelser derav. |
AU2003279004B2 (en) * | 2002-09-28 | 2009-10-08 | Massachusetts Institute Of Technology | Influenza therapeutic |
US20040242518A1 (en) * | 2002-09-28 | 2004-12-02 | Massachusetts Institute Of Technology | Influenza therapeutic |
US20040138154A1 (en) * | 2003-01-13 | 2004-07-15 | Lei Yu | Solid surface for biomolecule delivery and high-throughput assay |
WO2004091578A2 (en) * | 2003-04-09 | 2004-10-28 | Biodelivery Sciences International, Inc. | Novel encochleation methods, cochleates and methods of use |
US8592368B2 (en) * | 2003-12-19 | 2013-11-26 | University Of South Florida | JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection |
WO2005113770A1 (en) * | 2004-05-13 | 2005-12-01 | Institut Gustave Roussy | Anti-rhoa and -rhoc sirnas and therapeutic compositions comprising them. |
CA2662560A1 (en) * | 2006-09-15 | 2008-03-20 | Fmc Biopolymer As | Oligonucleotide non-viral delivery systems |
-
2007
- 2007-07-06 DK DK07764504.2T patent/DK2037899T3/da active
- 2007-07-06 EP EP11167103A patent/EP2397123A1/de not_active Withdrawn
- 2007-07-06 AT AT07764504T patent/ATE503469T1/de not_active IP Right Cessation
- 2007-07-06 EP EP10187562A patent/EP2295045A1/de not_active Withdrawn
- 2007-07-06 EP EP07764504A patent/EP2037899B1/de not_active Not-in-force
- 2007-07-06 CA CA2706124A patent/CA2706124A1/en not_active Abandoned
- 2007-07-06 WO PCT/DK2007/050084 patent/WO2008003329A2/en active Application Filing
- 2007-07-06 US US12/307,566 patent/US20100015232A1/en not_active Abandoned
- 2007-07-06 ES ES07764504T patent/ES2362376T3/es active Active
- 2007-07-06 DE DE602007013559T patent/DE602007013559D1/de active Active
Also Published As
Publication number | Publication date |
---|---|
EP2397123A1 (de) | 2011-12-21 |
DE602007013559D1 (de) | 2011-05-12 |
WO2008003329A2 (en) | 2008-01-10 |
EP2295045A1 (de) | 2011-03-16 |
US20100015232A1 (en) | 2010-01-21 |
EP2037899B1 (de) | 2011-03-30 |
CA2706124A1 (en) | 2008-01-10 |
ES2362376T3 (es) | 2011-07-04 |
WO2008003329A3 (en) | 2008-02-21 |
DK2037899T3 (da) | 2011-05-09 |
EP2037899A2 (de) | 2009-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE503469T1 (de) | Nanoteilchen zur abgabe von nukleinsäure | |
HK1257302A1 (zh) | 包含特異於靶dna的向導rna和cas蛋白質編碼核酸或cas蛋白質的用於切割靶dna的組合物及其用途 | |
CY1122617T1 (el) | Απαλλαγμενες prion συνθεσεις νανοσωματιδιων και μεθοδοι | |
EP4279610A3 (de) | Ribonukleinsäurereinigung | |
WO2008151022A3 (en) | Nucleic acid nanoparticles and uses therefor | |
BRPI0818374A8 (pt) | Substratos porosos hidrofílicos | |
WO2010026488A3 (en) | Methods and kits for nucleic acid sequencing | |
ATE502122T1 (de) | Chemisch modifizierte oligonukleotidprimer zur nukleinsäureamplifikation | |
WO2006110688A3 (en) | Rnai therapeutic for respiratory virus infection | |
WO2013165816A3 (en) | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS | |
WO2013143700A3 (en) | Artificial nucleic acid molecules comprising a 5'top utr | |
EP4269584A3 (de) | Selektive antisense-verbindungen und verwendungen davon | |
WO2008115851A3 (en) | Rnai therapeutic for respiratory virus infection | |
WO2012019168A3 (en) | Engineered nucleic acids and methods of use thereof | |
WO2008134761A3 (en) | Modification of biological targeting groups for the treatment of cancer | |
SG195194A1 (en) | Nanogels | |
EP2647711A3 (de) | Alternative Exportwege für über einen Vektor exprimierte RNA-Interferenz | |
WO2009108217A3 (en) | Compositions comprising k-ras sirna and methods of use | |
WO2009114475A3 (en) | Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use | |
DE502007006037D1 (de) | Multimer zur immunstimulation | |
WO2009074970A3 (en) | Means for delivery of nucleic acids active for gene silencing using synthetic polymers | |
WO2009039189A3 (en) | Compositions comprising stat3 sirna and methods of use thereof | |
WO2012177695A3 (en) | Hybrid polymerases having the ability to produce long amplicons | |
GB0917615D0 (en) | Method for increasing the speed of nucleic acid amplification reactions | |
WO2012170907A3 (en) | Polymerization of nucleic acids using proteins having low isoelectric points |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |